SVU - International Journal of Medical Sciences (Jan 2022)

Agonist hold Antagonist Protocol versus Antagonist Protocol in Intracytoplasmic Sperm Injection for Infertile Patients with Polycystic Ovary Syndrome

  • Hazem H. Ahmed,
  • Mahmoud I Alrashidy,
  • Osama A. M. Ali *,
  • Ahmed H. Abdellah

DOI
https://doi.org/10.21608/svuijm.2022.113449.1259
Journal volume & issue
Vol. 5, no. 1
pp. 273 – 279

Abstract

Read online

Background: Polycystic Ovary Syndrome (PCOS) is currently thought to emerge from a complex interaction of genetic and environmental traits.PolycysticOvarySyndrome is the most common endocrinopathy among reproductive-aged women Objectives: The aim of this study was to compare between agonist hold antagonist protocol and antagonist protocol in ICSI for Infertile patients with PCOsas regard the number of oocytes retrieved, fertilization rate, implantation rate and clinical pregnancy rate. Patients and methods: This was a prospective comparative study, which was conducted at Assisted Reproduction Unit at Qena University Hospital.This work had been conducted on infertile women with PCOS undergoing ICSI in ART unit in obstetrics and gynecology department, Qena University hospital from January 2019 to June 2020. Results: The number of implanted embryos was significantly higher in agonist hold antagonist protocol group compared to antagonist protocol group (p 0.05). Conclusion: GnRH agonistholdantagonist may be a preferred protocol for PCOS patients treated with ICSI in view of the reduction of the risk of OHSS, the shorter stimulation time and better pregnancy outcome.

Keywords